Black Titan (NASDAQ:BTTC – Get Free Report) is one of 48 public companies in the “Services – Computer Programming And Data Processing” industry, but how does it weigh in compared to its competitors? We will compare Black Titan to similar businesses based on the strength of its risk, dividends, profitability, analyst recommendations, earnings, valuation and institutional ownership.
Volatility and Risk
Black Titan has a beta of 1.38, meaning that its stock price is 38% more volatile than the S&P 500. Comparatively, Black Titan’s competitors have a beta of 0.54, meaning that their average stock price is 46% less volatile than the S&P 500.
Profitability
This table compares Black Titan and its competitors’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Black Titan | N/A | -108.60% | -95.64% |
| Black Titan Competitors | -63.65% | -919.53% | -68.53% |
Earnings and Valuation
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Black Titan | $180,000.00 | -$4.71 million | -0.54 |
| Black Titan Competitors | $250.54 million | -$80.63 million | -9.74 |
Black Titan’s competitors have higher revenue, but lower earnings than Black Titan. Black Titan is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
Institutional & Insider Ownership
56.4% of shares of all “Services – Computer Programming And Data Processing” companies are held by institutional investors. 0.7% of Black Titan shares are held by company insiders. Comparatively, 16.4% of shares of all “Services – Computer Programming And Data Processing” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Analyst Recommendations
This is a breakdown of current ratings and target prices for Black Titan and its competitors, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Black Titan | 1 | 0 | 0 | 0 | 1.00 |
| Black Titan Competitors | 99 | 204 | 221 | 14 | 2.28 |
As a group, “Services – Computer Programming And Data Processing” companies have a potential upside of 118.30%. Given Black Titan’s competitors stronger consensus rating and higher possible upside, analysts plainly believe Black Titan has less favorable growth aspects than its competitors.
Summary
Black Titan competitors beat Black Titan on 8 of the 13 factors compared.
Black Titan Company Profile
Titan Pharmaceuticals, Inc. is a biopharmaceutical company developingproprietary therapeutics for the treatment of central nervous system disorders, cancer, and other serious and life threatening diseases. In the central nervous system arena, the company is developing iloperidone, which is clinical testing for schizophrenia through a licensing and development agreement with Novartis Pharma AG. Novartis has tradenamed the product Zomaril.
Receive News & Ratings for Black Titan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Black Titan and related companies with MarketBeat.com's FREE daily email newsletter.
